RE:Sortilin 1 Promotes Hepatocellular Carcinoma This is a July 2022 article from a lab in China. I guess they're essentially showing what others have presented on the correlation between high sortilin expression and survivability --the worse the cancer, the higher the sortilin expression and the lower your probability of survival. So far, THTX has not mentioned liver cancer as one in the basket trial and I don't recall it being one in the original KOL presentation material from a few years ago mentioned as a high sort1 target to go after.
As I was looking through the charts on this, it did bring up a question in my mind that maybe the more science-oriented posters can offer a thought or two on. And that is, if TH1902 works due to the overexpression of sort1 typically seen in late stage solid tumor cancers, as it works to lower the tumor burden and cancer spread, does this reversion also lower the expression? In other words, if I take a stage 4/5 cancer and effectively reverse it back down to a stage 2/1 or less, won't that effect the efficacy of TH1902 going forward?
I suppose that's the problem with many cancer drugs and perhaps why there can still be many side effects as they improve. But for one that whose target is correlated with the severity of the disease, I guess there's a tipping point in which it's effectiveness is lessened. The pre-clinical didn't show that and maybe it's all about getting as much in the tumor to do it's thing as you can in the early stage and then you can modulate it lower if you need to. Anyway, a question for the scientists.
https://pubmed.ncbi.nlm.nih.gov/35847356/
Joemare wrote: Sortilin 1 Promotes Hepatocellular Carcinoma Cell Proliferation and Migration by Regulating Immune Cell Infiltration . 2022 Jul 8;2022:6509028. doi: 10.1155/2022/650902